ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 166 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2018. The put-call ratio across all filers is 9.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $780,906 | -38.7% | 19,474 | -8.8% | 0.01% | -41.7% |
| Q2 2022 | $1,273,000 | +46.0% | 21,348 | +120.8% | 0.01% | +33.3% |
| Q3 2021 | $872,000 | +294.6% | 9,670 | +317.4% | 0.01% | +350.0% |
| Q2 2021 | $221,000 | -20.8% | 2,317 | -64.6% | 0.00% | -71.4% |
| Q4 2019 | $279,000 | -68.4% | 6,545 | -52.9% | 0.01% | -77.4% |
| Q2 2019 | $883,000 | -28.0% | 13,900 | -21.5% | 0.03% | -27.9% |
| Q1 2019 | $1,227,000 | -16.0% | 17,700 | -47.3% | 0.04% | -23.2% |
| Q4 2018 | $1,460,000 | -47.2% | 33,607 | -7.2% | 0.06% | -54.5% |
| Q3 2018 | $2,763,000 | +35.2% | 36,200 | -9.6% | 0.12% | -19.6% |
| Q1 2018 | $2,043,000 | +592.5% | 40,050 | +823.4% | 0.15% | +410.0% |
| Q1 2017 | $295,000 | – | 4,337 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |